Loading...
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
BACKGROUND: The identification of molecular and genetic markers to predict or monitor the efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal cancer (mCRC). METHODS: Plasma levels of vascular endothelial growth factor (VEGF), placental growth factor (PlGF),...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3078596/ https://ncbi.nlm.nih.gov/pubmed/21407216 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.85 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|